



## **Seal Rock Therapeutics Receives Small Business Innovation Research Grant from National Institutes of Health to Support Novel Therapy for Acute Alcoholic Hepatitis**

**Seattle, WA, March 29, 2023** – Seal Rock Therapeutics, Inc., a clinical stage company developing first-in-class and best-in-class kinase inhibitors, today announced it has been awarded a \$358,000 grant from the National Institutes of Health Department of Health and Human Services, National Institute on Alcohol Abuse and Alcoholism to support evaluation of SRT-015, a next-generation, liver-selective inhibitor of Apoptosis Signal-reducing Kinase 1 (ASK1) as a treatment for acute alcoholic hepatitis.

“We appreciate this award to support further evaluation of SRT-015 for alcoholic hepatitis,” said Neil McDonnell, CEO of Seal Rock. “Our preclinical and clinical data to date have demonstrated that SRT-015 is well differentiated and support its further advancement into the clinic.”

This support is provided under award number R43AA029931.

### **About SRT-015**

SRT-015 is a next generation inhibitor of ASK1 developed internally by Seal Rock Therapeutics. Optimized to overcome the liabilities of selonsertib, and with a liver-preferential distribution, SRT-015 is positioned as a first-in-class product candidate for NASH and AH.

### **About Seal Rock Therapeutics**

Seal Rock Therapeutics is a privately held, clinical stage company based in Seattle focused on developing first-in-class and best-in-class treatments for severe diseases with limited or no available therapies. Seal Rock is led by an experienced management team with a track record of successful drug discovery, development and commercialization. The company’s clinical-stage lead product candidate, SRT-015, is a highly optimized, first-in-class ASK1 inhibitor. Seal Rock is also developing preclinical-stage brain-penetrant ASK1/LRRK2 dual kinase inhibitors for treatment of neurodegenerative conditions such as Parkinson’s disease and ALS.

For more information, please visit [www.sealrocktx.com](http://www.sealrocktx.com)

# # #

**Media Contact:**

Julie Rathbun  
Rathbun Communications  
[Julie@rathbuncomm.com](mailto:Julie@rathbuncomm.com)  
206-769-9219